{"nctId":"NCT01849068","briefTitle":"Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study","startDateStruct":{"date":"2013-06"},"conditions":["Metabolic Syndrome X"],"count":20,"armGroups":[{"label":"Ezetimibe","type":"EXPERIMENTAL","interventionNames":["Drug: Ezetimibe"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Ezetimibe","otherNames":["Ezetrol"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men aged between 18-60 years\n* Waist circumference \\> 102 cm\n* HDL-cholesterol \\< 1.1 mmol/L\n* Triglycerides \\> 1.7 mmol/L\n* Fasting blood glucose \\> 6.1 mmol/L\n* Normal blood pressure (\\<130/85)\n\nExclusion Criteria:\n\n* Women\n* Men \\< 18 or \\> 60 years\n* Smokers (\\> 1 cigarette/day)\n* Body weight variation \\> 10% during the last 6 months prior to the study baseline\n* Subjects with a previous history of cardiovascular disease\n* Subjects with type 2 diabetes\n* Subjects with a monogenic dyslipidemia\n* Subjects on hypertension medications or medications known to affect lipoprotein metabolism or the integrity of gastrointestinal mucosa\n* Subjects with endocrine or gastrointestinal disorders\n* History of alcohol or drug abuse within the past 2 years\n* Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions","description":"We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).\n\nWe combined the results at the end of each placebo phase from both sequence (average and standard deviation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110531","spread":"32604"},{"groupId":"OG001","value":"95140","spread":"31840"}]}]}]},{"type":"SECONDARY","title":"Change in Intestinal mRNA Expression Levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA Reductase Between the Two 12-week Interventions","description":"We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).\n\nWe combined the results at the end of each placebo phase from both sequence (average and standard deviation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"354911","spread":"102607"},{"groupId":"OG001","value":"311268","spread":"88237"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9079","spread":"5816"},{"groupId":"OG001","value":"8091","spread":"6131"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"193012","spread":"32787"},{"groupId":"OG001","value":"182349","spread":"36681"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"454298","spread":"97707"},{"groupId":"OG001","value":"448686","spread":"138746"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"271811","spread":"111688"},{"groupId":"OG001","value":"283863","spread":"132434"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125315","spread":"46842"},{"groupId":"OG001","value":"129551","spread":"63246"}]}]}]},{"type":"SECONDARY","title":"Change in Intestinal Protein Levels of LDL Receptor Between the Two 12-week Interventions","description":"We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).\n\nWe combined the results at the end of each placebo phase from both sequence (average and standard deviation).","classes":[]},{"type":"SECONDARY","title":"Change in Protein Levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA Reductase Between the Two 12-week Interventions","description":"We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).\n\nWe combined the results at the end of each placebo phase from both sequence (average and standard deviation).","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":[]}}}